ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag disease medicine policy

Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
The Lancet Alters Editorial Practices After Surgisphere Scandal
Catherine Offord | Sep 22, 2020 | 4 min read
The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.
The Surgisphere Scandal: What Went Wrong?
Catherine Offord | Oct 1, 2020 | 10+ min read
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019 | 6 min read
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Elias A. Zerhouni
Ted Agres | Jul 7, 2002 | 4 min read
In the mid-1980s, cardiologists faced a particularly vexing problem: how to measure, accurately and noninvasively, the thickness of heart tissue as it changed over time. Elias A. Zerhouni, a young radiology professor at Johns Hopkins School of Medicine, struggled over the issue with a small team of physicists. "One day, he walked into the room with this incredible smile on his face, like you would have if you made a great molecular discovery," recalls Myron Weisfeldt, director of Hopkins' Depart
Senior Scientists Quit Europe
Silvia Sanides | Jun 1, 2003 | 7 min read
©Paul Barton, Corbis Rigid retirement policies are prompting scientists to flee Europe at the height of their professional lives to start second careers in the United States. Many of these researchers are still conducting experiments and are in no mood to slow down. But because nearly all European universities are government run, professors are left little choice when they reach mandatory retirement age, which in most countries is 65 years or even younger. Some scientists leaving for the

Run a Search

ADVERTISEMENT